Copyright
©2009 Baishideng.
World J Gastrointest Oncol. Oct 15, 2009; 1(1): 62-68
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.62
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.62
Table 3 Clinicopathological characteristics of the transitional cell carcinoma group and their relation to VEGF immunostaining n (%)
Variable | n | VEGF | P value | |
Positive | Negative | |||
Age (yr) | ||||
≤ 50 | 11 (22) | 5 (10) | 6 (12) | 0.364 |
> 50 | 39 (78) | 12 (24) | 27 (54) | |
Sex | ||||
Male | 42 (84) | 16 (32) | 26 (52) | 0.161 |
Female | 8 (16) | 1 (2) | 7 (14) | |
Grade | ||||
G2 | 18 (36) | 6 (12) | 12 (24) | 0.941 |
G3 | 32 (64) | 11 (22) | 21 (42) | |
Stage | ||||
pT1 | 8 (16) | 3 (6) | 5 (10) | 0.935 |
pT2 | 28 (56) | 9 (18) | 19 (38) | |
pT3 | 7 (14) | 3 (6) | 4 (8) | |
pT4 | 7 (14) | 2 (4) | 5 (10) | |
Node status | ||||
Positive | 6 (12) | 1 (2) | 5 (10) | 0.339 |
Negative | 44 (88) | 16 (32) | 28 (56) |
-
Citation: El-Chennawi FA, Auf FA, Metwally SS, Mosaad YM, Shaaban AA, El-Baz MA, Tawhid ZE, Lotfy ZF. Vascular endothelial growth factor,
p53 , and theH-ras oncogene in Egyptian patients with bladder cancer. World J Gastrointest Oncol 2009; 1(1): 62-68 - URL: https://www.wjgnet.com/1948-5204/full/v1/i1/62.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v1.i1.62